Pathological features and immune microenvironment in HER-2 intratumoral heterogeneous breast cancers.
10.3760/cma.j.cn112152-20201027-00939
- VernacularTitle:人表皮生长因子受体2瘤内异质性乳腺癌的病理学特征和免疫微环境
- Author:
Yi Ling YANG
1
;
Yuan Ming SONG
1
;
Hui Qin XUE
1
;
Hui SUN
1
;
Ya Qing LI
1
;
Xiao Long QIAN
1
;
Jiao JIAO
1
;
Kun Peng LI
1
;
Heng ZHANG
2
;
Xiao Jing GUO
1
Author Information
1. Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, KeyLaboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Key Laboratoryof Breast Cancer Prevention and Theraphy, Ministry of Education, Tianjin 300060, China.
2. Department of Oncology, Institute of Integrative Oncology, Tianjin Union Medical Center of Nankai University, Tianjin 300121, China.
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Human epidermal growth factor receptor 2;
Intratumor heterogeneity;
Programmed cell death-ligand 1;
Tumor immune microenvironment;
Tumor infiltrating lymphocytes
- MeSH:
Humans;
Female;
Breast Neoplasms/pathology*;
Retrospective Studies;
B7-H1 Antigen/metabolism*;
Lymphocytes, Tumor-Infiltrating/pathology*;
Carcinoma;
Tumor Microenvironment;
Triple Negative Breast Neoplasms/pathology*;
Prognosis;
Biomarkers, Tumor/metabolism*
- From:
Chinese Journal of Oncology
2023;45(2):165-169
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To observe the clinical pathology features, and immune microenvironment of HER-2 intratumoral heterogeneity breast cancer. Methods: Thirty cases of HER-2 intratumoral heterogeneous breast cancer were retrospectively analyzed in Tianjin Medical University Cancer Institute and Hospital from November 2017 to June 2020. HER-2 expression was detected by immunohistochemistry and verified by dual color silver-enhanced in-situ hybridization (D-SISH). HER-2 intratumoral positive and negative regions were divided. The pathological characteristics, subtype, and the level of tumor infiltrating lymphocytes (TILs) and the expression of programmed cell death-ligand 1 (PD-L1) were evaluated respectively. Results: The proportion of HER-2 positive cells of the breast cancer ranged from 10% to 90%. The pathological type was mainly invasive non-special typecarcinoma. Six cases presented different pathological types between HER-2 positive and negative regions. The HER-2-positive areas included 2 cases of carcinoma with apocrine differentiation, and the negative areas included 2 cases of invasive micropapillary carcinoma, 1 case of invasive papillary carcinoma, and 1 case of carcinoma with apocrine differentiation. In HER-2 positive regions, 17 cases were Luminal B and 13 cases were HER-2 overexpressed types. There were 22 cases of Luminal B and 8 cases of triple negative tumors in the HER-2 negative areas. The levels of TILs in HER-2 positive and negative areas accounted for 53.3% (16/30) and 26.7% (8/30), respectively, with a statistically significant difference (P=0.035). The positive expression of PD-L1 in HER-2 positive area and HER-2 negative area were 6 cases and 9 cases, respectively. Among 8 cases with HER-2 negative regions containing triple negative components, 4 cases were positive for PD-L1 expression. Conclusions: In the case of HER-2 intratumoral heterogeneity, it is necessary to pay attention to both HER-2 positive and negative regions, and evaluate subtype separately as far as possible. For HER-2 intratumoral heterogeneous breast cancer containing triple negative components, the treatment mode can be optimized by refining the intratumoral expression of PD-L1.
